stockrowAxsome Therapeutics, Inc.
AXSM Healthcare Biotechnology
Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +73.9%
- Free cash flow
- −1,078.3%
- Total debt
- +4.04%
Quarter to September 2026, against a year earlier
Follow AXSM
Alert me
Axsome Therapeutics, Inc. (AXSM) Return on equity
Axsome Therapeutics, Inc.'s return on equity over the twelve months to 30 September 2026 was −175.6%, up 76.5 percentage points from fiscal 2025 (−252.1%). Over the past ten years it has ranged from −350.8% (fiscal 2018) to −56.5% (fiscal 2015); the current reading is higher than 27% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −252.1% | (20.48) |
| FY2024 | −231.6% | (72.42) |
| FY2023 | −159.2% | 139.76 |
| FY2022 | −299.0% | (97.46) |
| FY2021 | −201.5% | (131.15) |
| FY2020 | −70.4% | 5.72 |
| FY2019 | −76.1% | 274.70 |
| FY2018 | −350.8% | (199.59) |
| FY2017 | −151.2% | (71.20) |
| FY2016 | −80.0% | (23.51) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 5.38% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 0.00% |
| ORKA Oruka Therapeutics, Inc. compare | −18.3% |
| PRAX Praxis Precision Medicines, Inc. compare | −38.9% |
| IONS Ionis Pharmaceuticals, Inc. compare | −105.5% |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −167.5% |
| AXSM Axsome Therapeutics, Inc. | −175.6% |
| ABVX Abivax SA Sponsored ADR compare | −249.8% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −760.0% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on AXSM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement